<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1086">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830774</url>
  </required_header>
  <id_info>
    <org_study_id>TCAI-unCOVer1</org_study_id>
    <nct_id>NCT04830774</nct_id>
  </id_info>
  <brief_title>Natural History of COVID-19-Related Atrial Fibrillation</brief_title>
  <acronym>unCOVer-AF</acronym>
  <official_title>Natural History and Recurrence Rate of Atrial Fibrillation After the First, COVID-19-Related Atrial Arrhythmic Episode: A Prospective Evaluation Using Continuous Cardiac Rhythm Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Cardiac Arrhythmia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Cardiac Arrhythmia Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The unCOVer-AF prospective, multicenter registry aims at determining the natural history of&#xD;
      atrial fibrillation (AF) via continuous cardiac rhythm monitoring in patients with a first&#xD;
      arrhythmic episode during COVID-19 hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus Disease 2019 (COVID-19) is a novel coronavirus strain disease, which has rapidly&#xD;
      spread worldwide with more than 100 million confirmed cases to date. COVID-19 is mainly&#xD;
      characterized by respiratory symptoms; however, patients can exhibit a wide range of clinical&#xD;
      manifestations, including cardiovascular complications. Among them, supraventricular and&#xD;
      ventricular arrhythmias have been described in patients at different stages of disease&#xD;
      severity. According to a recent study on 9564 COVID-19 patients, 17.6% developed AF during&#xD;
      hospitalization, 65.7% of whom without a past arrhythmic history.&#xD;
&#xD;
      Several factors (e.g., hypoxia, systemic inflammatory response, myocardial injury) may&#xD;
      interact with a preexisting substrate and act as a trigger for AF initiation. Nonetheless,&#xD;
      the pathophysiology of COVID-19-related new-onset AF remains elusive. It is unknown whether&#xD;
      the disease merely acts as a transient arrhythmia initiator or promotes long-term atrial&#xD;
      electrophysiological and structural changes which may facilitate AF recurrence and&#xD;
      progression.&#xD;
&#xD;
      Therefore, the investigators designed a multicenter, prospective registry to assess the&#xD;
      natural history of AF via continuous cardiac rhythm monitoring (ILR, PMK, ICD) in patients&#xD;
      with a first AF episode during COVID-19 hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF Burden</measure>
    <time_frame>3 years</time_frame>
    <description>AF burden is defined as cumulative duration of all AF episodes lasting ≥30 s from the first adjudicated AF episode onward, divided by total duration of monitoring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AF Progression</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to adjudicated ischemic stroke/transient ischemic attack (TIA)/systemic arterial embolism</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality, stroke and bleeding</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to adjudicated cardiovascular death</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <condition>Atrial Fibrillation New Onset</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients with new-onset AF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ILR, PMK, ICD</intervention_name>
    <description>Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.&#xD;
Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions</description>
    <arm_group_label>COVID-19 patients with new-onset AF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years;&#xD;
&#xD;
          -  Confirmed infection with SARS-CoV-2;&#xD;
&#xD;
          -  Patients with a first clinical episode of AF ≥30 s at admission or during&#xD;
             hospitalization for COVID-19;&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               1. implantation of an ILR, a PMK, or an ICD during COVID-19 hospitalization or&#xD;
                  within 30 days after hospital discharge, or&#xD;
&#xD;
               2. an ILR, a PMK, or an ICD implanted before COVID-19 hospitalization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of AF or flutter irrespective of type;&#xD;
&#xD;
          -  Moderate/severe mitral stenosis;&#xD;
&#xD;
          -  Mechanical prosthetic heart valve(s);&#xD;
&#xD;
          -  Kidney failure treated with permanent dialysis;&#xD;
&#xD;
          -  Any condition (e.g. psychiatric illness, dementia) or situation, that in the&#xD;
             investigators opinion could put the subject at significant risk, confound the study&#xD;
             results, or interfere significantly with the subject participation in the study;&#xD;
&#xD;
          -  Unwillingness to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenico G Della Rocca, MD</last_name>
    <role>Study Director</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Domenico G Della Rocca, MD</last_name>
    <phone>(512) 807-3150</phone>
    <email>domenicodellarocca@hotmail.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Magnocavallo, MD</last_name>
    <email>michelefg91@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiovascular/Respiratory Diseases, Nephrology, Anesthesiology, and Geriatric Sciences, Policlinico Umberto I, Sapienza University of Rome</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Unit, ASST-Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giovanni B Forleo, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marco Schiavone, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mountantonakis SE, Saleh M, Fishbein J, Gandomi A, Lesser M, Chelico J, Gabriels J, Qiu M, Epstein LM; Northwell COVID-19 Research Consortium. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021 Jan 22. pii: S1547-5271(21)00040-0. doi: 10.1016/j.hrthm.2021.01.018. [Epub ahead of print]</citation>
    <PMID>33493650</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Cardiac Arrhythmia Research Foundation</investigator_affiliation>
    <investigator_full_name>Andrea Natale</investigator_full_name>
    <investigator_title>Executive Medical Director</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>COVID-19</keyword>
  <keyword>natural history</keyword>
  <keyword>stroke</keyword>
  <keyword>loop recorder</keyword>
  <keyword>cardiac implantable electronic device</keyword>
  <keyword>remote monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

